Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00972517
First received: September 3, 2009
Last updated: November 17, 2011
Last verified: June 2011

September 3, 2009
November 17, 2011
September 2009
November 2010   (final data collection date for primary outcome measure)
Humoral immune response in terms of haemagglutination inhibition (HI) antibodies [ Time Frame: At Day 0, Day 21, Day 42 and at Month 6 + 7 days ] [ Designated as safety issue: No ]
Humoral immune response in terms of haemagglutination inhibition (HI) antibodies [ Time Frame: At Day 42 and at Month 6 + 7 days ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00972517 on ClinicalTrials.gov Archive Site
  • Humoral immune response in terms of HI antibodies [ Time Frame: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 days, Month 12 ] [ Designated as safety issue: No ]
  • Humoral immune response in terms of neutralising antibodies [ Time Frame: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 days, Month 12 ] [ Designated as safety issue: No ]
  • Occurrence of local and general symptoms [ Time Frame: During a 7-day follow-up period after each vaccination ] [ Designated as safety issue: No ]
  • Occurrence of unsolicited symptoms [ Time Frame: During a 21-day follow-up period after first vaccination, a 63-day follow-up after second vaccination and a 30-day follow-up after booster vaccination ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events, adverse events of specific interest or potential mediated-disease, medically attended events [ Time Frame: During the entire study period (Day 0 - Month 18) ] [ Designated as safety issue: No ]
  • Occurrence of subjects with normal or abnormal biochemical parameters [ Time Frame: At Day 0, Day 21, Day 42, Month 6 and Month 6 + 7 days ] [ Designated as safety issue: No ]
  • Humoral immune response in terms of HI antibodies [ Time Frame: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 days, Month 12, Month 18 ] [ Designated as safety issue: No ]
  • Humoral immune response in terms of neutralising antibodies [ Time Frame: At Day 0, Day 21, Day 42, Month 6, Month 6 + 7 days, Month 12, Month 18 ] [ Designated as safety issue: No ]
  • Occurrence of local and general symptoms [ Time Frame: During a 7-day follow-up period after each vaccination ] [ Designated as safety issue: No ]
  • Occurrence of unsolicited symptoms [ Time Frame: During a 21-day follow-up period after first vaccination, a 63-day follow-up after second vaccination and a 30-day follow-up after booster vaccination ] [ Designated as safety issue: No ]
  • Occurrence of serious adverse events, adverse events of specific interest, medically attended events [ Time Frame: During the entire study period (Day 0 - Month 18) ] [ Designated as safety issue: No ]
  • Occurrence of subjects with normal or abnormal biochemical parameters [ Time Frame: At Day 0, Day 21, Day 42, Month 6 and Month 6 + 7 days ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (GSK2340272A) in Children Aged 3 to 17 Years

The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.

This Protocol Posting has been updated following Protocol amendment 1, October 2009. The impacted section are the study design section, the outcomes measures section and the intervention section.

Interventional
Phase 3
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Influenza Infection
Biological: GSK investigational vaccine GSK2340272A
Three intramuscular injections
Experimental: Group A
Subjects receiving alternative dose of GSK23440272A vaccine
Intervention: Biological: GSK investigational vaccine GSK2340272A
Garcia-Sicilia J, Gillard P, Carmona A, Tejedor JC, Aristegui J, Merino JM, Behre U, Caplanusi A, Vaman T, Dieussaert I. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine. 2011 Jun 10;29(26):4353-61. doi: 10.1016/j.vaccine.2011.04.011. Epub 2011 Apr 17.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
245
November 2010
November 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.
  • Children, male or female, aged between 3 and 17 years at the time of the first study vaccination.
  • Written informed consent obtained from the subject parent(s) or LAR(s) of the subject. Assent obtained from the subject when applicable.
  • Healthy children as established by medical history and clinical examination when entering into the study.
  • Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user device.

Exclusion Criteria:

  • Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.
  • Clinically or virologically confirmed influenza infection within six months preceding the study start.
  • Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.
  • Acute disease and/or fever at the time of enrolment
  • Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.
  • Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.
  • Previous administration of any H1N1 A/California-like vaccine.
  • Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study.
  • If the subject is female and if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.
  • Any known or suspected allergy to any constituent of influenza vaccines; a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.
  • Known use of an analgesic or antipyretic medication within 12 hours prior to first vaccination.
  • Child in Care.
Both
3 Years to 17 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00972517
113638
Not Provided
Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
GlaxoSmithKline
Not Provided
Study Director: GSK Clinical Trials GlaxoSmithKline
GlaxoSmithKline
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP